Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.


Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.


You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences

Pacific Biosciences of California, Inc. Announces Third Quarter 2015 Financial Results

Thursday, October 22, 2015

MENLO PARK, Calif., Oct. 22, 2015 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced financial results for its third quarter ended September 30, 2015.

Revenue for the third quarter of 2015 totaled $13.9 million, compared to $20.6 million for the third quarter of 2014. Third quarter 2015 revenue includes product and service revenue of $10.3 million and $3.6 million of contractual revenue, while third quarter 2014 revenue includes product and service revenue of $8.9 million and $11.7 million of contractual revenue. Third quarter 2015 contractual revenue reflects $3.6 million of quarterly amortization of the upfront Roche payment while third quarter 2014 contractual revenue includes $10.0 million of milestone revenue and $1.7 million of quarterly amortization of the upfront Roche payment.

Gross profit for the third quarter of 2015 was $6.6 million, resulting in a gross margin of 47.1%, compared to gross profit of $13.2 million and a gross margin of 63.8% for the third quarter of 2014.

Operating expenses totaled $3.9 million for the third quarter of 2015, which consisted of aggregate expenses of $26.9 million offset by a one-time gain on lease amendments of $23.0 million, compared to the operating expenses of $21.6 million for the third quarter of 2014. Operating expenses for the third quarters of 2015 and 2014 included non-cash stock-based compensation of $2.9 million and $2.2 million, respectively.

Net income for the third quarter of 2015 was $1.8 million primarily driven by the one-time gain on lease amendments of $23.0 milion, compared to a net loss of $9.2 million for the third
quarter of 2014. Net income per share for both basic and diluted for the third quarter of 2015 was $0.02 per share as compared to net loss per share for the third quarter of 2014 of $0.13 per share.

Cash and investments at September 30, 2015 totaled $58.9 million, compared to $101.3 million at December 31, 2014.

Quarterly Conference Call Information 

Management will host a quarterly conference call to discuss its third quarter 2015 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330. The call will be webcast live and will be available for replay at Pacific Biosciences’ website at http://investor.pacificbiosciences.com/.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) Technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Pacific Biosciences’ technology provides the industry’s highest consensus accuracy over the longest read lengths in combination with the ability to detect real-time kinetic information. The Sequel System, including consumables and software, provides a simple, fast, end-to-end workflow for SMRT Sequencing.  More information is available at www.pacb.com.

Forward-Looking Statements

All statements in this press release that are not historical are
forward-looking statements, including, among other things, statements relating to the timeline for Pacific Biosciences’ potential development of products for Roche, future payments from our landlord in return for our agreement to amend our current leases, the attributes of the Sequel System and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.


Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statement of Operations

(amounts in thousands, except per share amounts)
Three-month Periods Ended   Nine-month Periods Ended
September 30,   September 30,
2015   2014   2015   2014
Product revenue $  7,570 $  6,762 $  27,703 $  22,376
Service and other revenue  2,751  2,165  8,010  6,226
Contractual revenue  3,596  11,696  20,788  15,088
Total revenue  13,917  20,623  56,501  43,690
Cost of Revenue:
Cost of product revenue  5,119  5,608  23,289  19,048
Cost of service and other revenue  2,247  1,853  6,228  5,678
Total cost of revenue    7,366    7,461    29,517    24,726
Gross profit  6,551  13,162  26,984  18,964
Operating Expense:
Research and development  16,162  11,693  45,688  35,899
Sales, general and administrative  10,818  9,882  32,411  28,025
Gain on lease amendments  (23,043 )  —  (23,043 )  —
Total operating
 3,937  21,575  55,056  63,924
Operating income (loss)  2,614  (8,413 )  (28,072 )  (44,960 )
Interest expense  (741 )  (716 )  (2,153 )  (2,103 )
Other expense, net  (52 )  (34 )  (62 )  (122 )
Net income (loss) $  1,821 $  (9,163 ) $  (30,287 ) $  (47,185 )
Net income (loss) per share:
Basic $  0.02 $  (0.13 ) $  (0.41 ) $  (0.68 )
Diluted $  0.02 $  (0.13 ) $  (0.41 ) $  (0.68 )
Weighted average shares outstanding used in calculating net income (loss) per share
Basic  75,205  70,740  74,699  69,716
Diluted  80,176  70,740  74,699  69,716


Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets
(amounts in thousands)
September 30,   December 31,
2015   2014
Cash and investments $  58,909 $  101,348
Accounts receivable  4,164  3,406
Inventory  11,621  11,335
Prepaid and other current assets  11,513  1,671
Property and equipment  7,855  6,601
Other long-term Assets  5,715  162
Total Assets $  99,777 $  124,523
Liabilities and Stockholders’ Equity
Accounts payable $  6,097 $  5,608
Accrued expenses  11,342  11,441
Deferred service revenue  7,553  7,250
Deferred contractual revenue  15,732  26,520
Other liabilities  1,950  3,687
Financing derivative  925  944
Notes payable  14,808  14,124
Stockholders’ equity  41,370  54,949
Total Liabilities and Stockholders’ Equity $  99,777 $  124,523



Trevin Rard



Primary Logo

Source: Pacific Biosciences, Inc.

News Provided by Acquire Media